Acumen Pharmaceuticals Inc ABOS
News
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024